17 Capital Partners’s Neurocrine Biosciences NBIX Stock Holding History

17 Capital Partners’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$775K	Buy	4,600 +15	+0.3%	+$2.23K	0.35%	96
2026 Q1	$604K	Buy	4,585 +250	+6%	+$33.2K	0.31%	107
2025 Q4	$615K	Buy	4,335 +770	+22%	+$112K	0.32%	97
2025 Q3	$500K	Hold	3,565	–	–	0.27%	104
2025 Q2	$448K	Buy	3,565 +650	+22%	+$74.5K	0.26%	102
2025 Q1	$322K	Buy	2,915 +1,205	+70%	+$153K	0.21%	119
2024 Q4	$233K	Sell	1,710 -4,136	-71%	-$512K	0.15%	123
2024 Q3	$674K	Buy	5,846 +2,881	+97%	+$395K	0.44%	72
2024 Q2	$408K	Buy	+2,965	New	+$407K	0.29%	93

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

17 Capital Partners's NBIX Position: Q2 2026 in Review

17 Capital Partners increased its Neurocrine Biosciences (NBIX) stake by 0.33% in Q2 2026, buying an estimated $2.23K and bringing the position to 4,600 shares worth $775K. The position accounts for 0.35% of the portfolio, ranked #96.

17 Capital Partners first reported a position in NBIX in Q2 2024 and has held it in 9 quarters since. 778 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

17 Capital Partners held 4,600 shares of Neurocrine Biosciences worth $775K as of Q2 2026.
17 Capital Partners bought 15 Neurocrine Biosciences shares in Q2 2026, an estimated $2.23K.
Neurocrine Biosciences made up 0.35% of 17 Capital Partners's portfolio in Q2 2026, its #96 holding.
17 Capital Partners first reported a position in Neurocrine Biosciences in Q2 2024 and has held it in 9 quarters since.
778 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on 17 Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.